Coeptis Pharmaceuticals, Inc. is a privately held biopharmaceutical company engaged in the acquisition, development and commercialization of branded and generic pharmaceutical products. The company owns an expansive portfolio of generic and 505(b)(2) assets, various novel small molecule therapies for neurological based indications and biotechnology assets, which includes a stake in an immuno-discovery company with platform RNA modulation technologies for optimized gene and cell therapies with a focus on cancers, encompassing a wide array of treatments such as CAR-T and CAR-NK. Headquartered near Pittsburgh, PA, Coeptis Pharmaceuticals holds a robust pipeline of products in various stages of development and commercialization.
Our emphasis are products that present unique opportunities for the healthcare community including challenging development programs, or modified generics. We work across all therapeutic areas to identify, develop, and commercialize products that are marketed to retail and non-retail prescription drug channels.